Considering the critical role of BTK in several B-cell malignancies, a BTK-specific inhibitor, ibrutinib, is currently used to treat some types of lymphoma (such as mantle cell lymphoma) and chronic lymphocytic leukemia [13]. This evidence concerns the gene BTK and mantle cell lymphoma.